CAS 202825-46-5

Safinamide mesylate

Description:

Safinamide mesylate is a pharmaceutical compound primarily used in the treatment of Parkinson's disease. It functions as a dual-action medication, exhibiting both dopaminergic and non-dopaminergic properties. The chemical structure of safinamide includes a phenyl group and a sulfonamide moiety, which contribute to its pharmacological activity. It acts as a selective inhibitor of the enzyme monoamine oxidase B (MAO-B), thereby increasing the levels of dopamine in the brain, and also modulates glutamate release, which may help in managing motor symptoms associated with Parkinson's disease. Safinamide mesylate is typically administered orally and is known for its relatively favorable side effect profile compared to other treatments. Its solubility and stability characteristics make it suitable for formulation in various dosage forms. As with any medication, it is essential to consider potential interactions with other drugs and individual patient factors when prescribing safinamide mesylate. Overall, its unique mechanism of action and therapeutic benefits make it a valuable option in the management of Parkinson's disease.

Formula: C₁₇H₁₉FN₂O₂·CH₄O₃S

InChI: InChI=1S/C17H19FN2O2.CH4O3S/c1-12(17(19)21)20-10-13-5-7-16(8-6-13)22-11-14-3-2-4-15(18)9-14;1-5(2,3)4/h2-9,12,20H,10-11H2,1H3,(H2,19,21);1H3,(H,2,3,4)/t12-;/m0./s1

InChI key: InChIKey=YKOCHIUQOBQIAC-YDALLXLXSA-N

SMILES: O(CC1=CC(F)=CC=C1)C2=CC=C(CN[C@H](C(N)=O)C)C=C2.S(C)(=O)(=O)O

Synonyms:

• (S)-2-[[4-[(3-Fluorobenzyl)oxy]benzyl]amino]propanamide methanesulfonate
• EMD 1195686 mesylate
• FCE-28073(R-isomer)
• Fce-26743
• Nw-1015
• N~2~-{4-[(3-fluorobenzyl)oxy]benzyl}-D-alaninamide methanesulfonate
• Pnu-151774E
• Propanamide, 2-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]-, (2S)-, methanesulfonate (1:1)
• Propanamide, 2-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]-, (2S)-, monomethanesulfonate
• Propanamide, 2-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]-, (S)-, monomethanesulfonate
• Safinamide mesilate
• Safinamide mesylate
• Safinamide methanesulfonate

Propanamide, 2-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]-, (2S)-, methanesulfonate (1:1)

CAS: 202825-46-5

Formula: C₁₈H₂₃FN₂O₅S

Purity: 98%

Color and Shape: Solid

Molecular weight: 398.4490

Ref: IN-DA0028G1

Safinamide mesylate salt

CAS: 202825-46-5

Formula: C₁₇H₁₉FN₂O₂·xCH₄O₃S

Molecular weight: 302.34 (free base b

Ref: 7W-GP1259

Safinamide Mesylate

CAS: 202825-46-5

Safinamide Mesylate

Purity: 99%

Molecular weight: 398.45g/mol

Ref: 54-PC109117

Safinamide mesylate

CAS: 202825-46-5

Safinamide mesylate

Purity: ≥98%

Molecular weight: 398.45g/mol

Ref: 54-BUP13421

Safinamide mesylate

CAS: 202825-46-5

Safinamide mesylate (EMD 1195686 mesylate) , a mesylate salt of Safinamide, can reversibly and specifically inhibit MAO-B (IC50: 98 nM), has 5918-fold

Formula: C₁₈H₂₃FN₂O₅S

Purity: 99.67%

Color and Shape: Solid

Molecular weight: 398.45

Ref: TM-T6651

Safinamide Mesylate

Controlled Product

CAS: 202825-46-5

Applications Safinamide mesylate is a potent and selective MAO-B inhibitor.
Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package

Formula: C₁₇H₁₉FN₂O₂·CH₄O₃S

Color and Shape: White To Off-White

Molecular weight: 398.45

Ref: TR-S819080

Safinamide mesylate

CAS: 202825-46-5

Safinamide mesylate is a drug that has been approved for the treatment of Parkinson's disease in Japan. It is an inhibitor of monoamine oxidase-B (MAO-B) and dopamine beta-hydroxylase, which are enzymes that break down dopamine. Safinamide mesylate has a chemical structure that reacts with hydrochloric acid to produce hydrogen gas and an acid formation. The drug also inhibits the conversion of dopamine to dihydroxyphenylacetic acid (DOPAC), which causes an accumulation of dopamine in the brain. Safinamide mesylate is metabolized by hydroxylation, deamination, and oxidation; its metabolites are excreted through urine. Pharmacokinetic studies have shown that safinamide mesylate has linear pharmacokinetics after intravenous injection or oral administration. Analysis by high performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) has revealed the presence of two metabolites

Formula: C₁₇H₁₉FN₂O₂•CH₄O₃S

Purity: Min. 95%

Color and Shape: White To Off-White Solid

Molecular weight: 398.45 g/mol

Ref: 3D-FS101887